Abstract
In the pharmaceutical industry, firms normally invest hundreds of millions of dollars in R & D and clinical trials on their drugs before it is sold in the market, while their generic medicine rivals are exempted from those requirements and enter the market at low cost with nominal investments. Developed countries medicine companies argue why generic drugs manufacturer should be permitted to reap fruits of patented medicine. However, generic drug manufacturers are of the opinion that big pharmaceutical houses are indulged in unfair practice and they are trying to get extra duration through evergreening patent. The basic formula of the compound is already known, and persons with ordinary skill and knowledge in the art can easily obtain the new crystalline form through general and routine operations. Hence, there is nothing novel to the development of a new crystalline form; instead, it should be manufacturer as a "discovery" of a natural substance, not as an "invention" that can be protected under patent law. Considering the global importance and political-economic stakes involved thereto this paper is an attempt to find out ways for maintaining balance between the Indian Biotech industry, global economic players and government liability to society.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
